Table 2.
Comparison of clinical parameters between baseline and SO therapy (258 PD patients)
| Parameter | Baseline | SO follow-up | p value |
|---|---|---|---|
| PB pills/day* | 10.0 (0.2) | 4.3 (0.2) | <0.0001 |
| Mineral and bone disease markers | |||
| Serum phosphorus, mg/dL | 6.59 (0.09) | 6.26 (0.09) | <0.0001 |
| Albumin-corrected calcium, mg/dL | 9.36 (0.04) | 9.31 (0.04) | 0.018 |
| Intact PTH, pg/mL | 468 (23) | 497 (22) | 0.032 |
| Nutritional and clearance parameters | |||
| Weight, kg | 86.8 (1.5) | 86.9 (1.5) | 0.8 |
| Serum albumin, g/dL | 3.70 (0.02) | 3.62 (0.02) | <0.0001 |
| Phosphorus-attuned albumin, ×103 | 0.6 (0.01) | 0.63 (0.01) | <0.0001 |
| nPCR, g/kg/day | 1.0 (0.03) | 1.0 (0.02) | 0.9 |
| Phosphorus-attuned nPCR, ×103 dL/kg/day | 0.17 (0.005) | 0.18 (0.004) | 0.044 |
| Serum creatinine, mg/dL | 12.0 (0.3) | 12.2 (0.3) | 0.001 |
| Kru, mL/min/1.73 m2 | 2.85 (0.20) | 2.47 (0.19) | 0.008 |
| PD Kt/V | 1.65 (0.05) | 1.70 (0.04) | 0.5 |
| Total Kt/V | 2.1 (0.06) | 2.1 (0.05) | 0.7 |
| Anemia and iron indices | |||
| Patients not receiving IV iron therapy (n = 93) | |||
| Ferritin, ng/mL | 801 (66) | 876 (65) | 0.018 |
| Transferrin saturation, n (%) | 38.5 (1.4) | 38.5 (1.3) | 0.9 |
| Hemoglobin, g/dL | 11.2 (0.2) | 11.3 (0.2) | 0.039 |
| Iron, mcg/dL | 98.1 (3.5) | 93.2 (3.2) | 0.077 |
| Patients receiving IV iron therapy (n = 165) | |||
| Ferritin, ng/mL | 748 (36) | 940 (34) | <0.0001 |
| Transferrin saturation, n (%) | 34.0 (0.9) | 38.4 (0.8) | <0.0001 |
| Hemoglobin, g/dL | 10.6 (0.1) | 10.7 (0.1) | 0.078 |
| Iron, mcg/dL | 85.8 (2.4) | 92.3 (2.1) | 0.005 |
Values are expressed as least-squared means (SE), p values compare least-squared means between treatment periods.
*
Pill burden at baseline was calculated only for patients who received PB prescriptions through FreseniusRx (n = 92). Follow-up PB pill burden for patients with no baseline binder available through FreseniusRx (n = 166) was found to be 4.3 SO pills/day.
Kru, residual urea clearance; nPCR, normalized protein catabolic rate; PD, peritoneal dialysis; PTH, parathyroid hormone; SO, sucroferric oxyhydroxide; PB, phosphate binder.